The Arnold Partnership v. Jon Dudas, Acting Under Secretary of Commerce for Intellectual Property, et al
Federal Circuit, March 25, 2004, Case 03-1339
“On summary judgment, the United States District Court for the Eastern District of Virginia ruled that the United States Patent and Trademark Office (PTO) properly denied an application for extending the term of U.S. Patent No. 4,587,252 [the commercial embodiment of the ’252 patent is Vicoprofen® – a combination of hydrocodone bitartrate (a salt of hydrocodone) and ibuprofen] under 35 U.S.C. § 156. Arnold P’ship v. Rogan, 246 F. Supp. 2d 460 (E.D. Va. 2003). Because the district court did not err in upholding the PTO’s interpretation of § 156, this court affirms.”
Copy of the case here.

Related posts:

1. Knoll Pharmaceutical Company, Inc., et al. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir.)
2. Pellegrini v. Analog Devices, Inc. (Fed. Cir.)